Skip to main content

PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I Dissection

Active, not recruiting · Not applicable · NCT05174767

Conditions: Acute Aortic Dissection

At a glance

Research payments reported, 2025
$365,320
U.S. investigators named
17
Sites paid
19
Planned or actual enrollment
115

About the trial

Sponsor
Artivion Inc. (with Syneos Health)
Tested
AMDS (device)
Dates
Started 2022-05-27; completion 2029-12-06
Results posted
Not yet

Prospective, non-randomized, multicenter clinical investigation to assess the safety and effectiveness of AMDS in the treatment of patients with acute DeBakey type I dissection, with evidence of malperfusion, through open surgical repair.

From ClinicalTrials.gov, last updated 2025-01-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Artivion, Inc. reported $365,320 in research payments for this study in 2025 (53 payments).

Products named: Amds-Ascyrus Medical

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.